Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.48 |
| ▸ | TUBB | P07437 | 5/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.48 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.48 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.48 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.48 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724297 | 0.91 | CNR1 (0.44) | PDGFRBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL723931 | 0.89 | TUBB1 (0.57) | PDGFRBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL724651 | 0.89 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL725053 | 0.89 | PDGFRB (0.50) | PDGFRBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL15135838 | 0.88 | EGFR (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL723964 | 0.88 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4422699 | 0.88 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL724236 | 0.88 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3469479 | 0.88 | EGFR (0.47) | PDGFRBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL725347 | 0.88 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334242-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2016-05-10 | — | — | US | claimed |
| EP-2542081-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-01-09 | — | — | EP | claimed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| CN-119548495-A | Use of (substituted 1H-imidazol-4-yl) (3, 4, 5-trimethoxyphenyl) methanones for the treatment of coronaviruses | 维鲁公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4504183-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | Veru Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| CN-118984703-A | Methods of treating influenza and poxvirus infections | 维鲁公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20240180879-A1 | METHODS OF TREATING INFLAMMATION | VERU INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4320151-A1 | METHODS OF TREATING INFLAMMATION | Veru Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117396505-A | Methods of treating inflammation | 维鲁公司 | 2024-01-12 | — | — | CN | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | PDGFRB 2557/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | PDGFRB 2557/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20240180879-A1 | METHODS OF TREATING INFLAMMATION | IL1B, PYCARD, TUBB1 | PDGFRB 3698/4885TUBB4A 13/4885TUBB 6/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | PDGFRB 2557/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | PDGFRB 2557/4885TUBB4A 296/4885TUBB 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.